Breaking News

Financial Report: Charles River Laboratories

February 14, 2013

Revenues decline 4% in the quarter

Charles River Laboratories

4Q Revenues: $280.1 million(-4%)

4Q Earnings: $18.5 million(-32%)

FY Revenues: $1.1 billion (-1%)

FY Earnings: $97.9 million(-11%)

Comments: Research Models and Services (RMS) segment sales were down 6% to $171.8 million in the quarter, driven by lower sales of research models, offset by Endotoxin sales and Microbial Detection (EMD) business, which included the acquisition of Accugenix. Preclinical Services (PCS) segment sales were flat at $108.3 million. For the year RMS sales were $695.1 million, down 2% and PCS sales were $434.4 million, down 1%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks